Renaissance Technologies LLC lifted its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 35.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,295,600 shares of the medical instruments supplier’s stock after purchasing an additional 338,900 shares during the quarter. C.R. Bard makes up about 0.5% of Renaissance Technologies LLC’s holdings, making the stock its 17th biggest position. Renaissance Technologies LLC owned approximately 1.78% of C.R. Bard worth $409,552,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BCR. BlackRock Inc. increased its stake in shares of C.R. Bard by 1,365.7% during the 1st quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock worth $1,838,719,000 after purchasing an additional 6,893,346 shares during the last quarter. Alpine Associates Management Inc. acquired a new position in shares of C.R. Bard during the 2nd quarter worth $265,663,000. MARSHALL WACE ASIA Ltd acquired a new position in shares of C.R. Bard during the 1st quarter worth $132,062,000. Marshall Wace North America L.P. acquired a new position in shares of C.R. Bard during the 1st quarter worth $132,062,000. Finally, JPMorgan Chase & Co. increased its stake in shares of C.R. Bard by 363.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 466,183 shares of the medical instruments supplier’s stock worth $147,364,000 after purchasing an additional 365,588 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.80% of the stock is owned by insiders.

Shares of C.R. Bard, Inc. (NYSE BCR) traded up 0.40% during mid-day trading on Friday, reaching $318.63. 279,775 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $320.07 and its 200-day moving average is $299.22. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $324.58. The stock has a market cap of $23.16 billion, a price-to-earnings ratio of 41.83 and a beta of 0.60.

C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same period in the previous year, the company earned $2.54 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts expect that C.R. Bard, Inc. will post $11.84 EPS for the current year.

A number of research analysts recently issued reports on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. BidaskClub lowered shares of C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $292.00.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/24/renaissance-technologies-llc-has-409-55-million-stake-in-c-r-bard-inc-bcr.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.